Testosterone and prolactin increase carboxypeptidase‐D and nitric oxide levels to promote survival of prostate cancer cells
- 17 June 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (4) , 450-460
Abstract
BACKGROUND: Plasma‐membrane carboxypeptidase‐D (CPD) releases arginine from extracellular substrates. Arginine is converted intracellularly to nitric oxide (NO). This study determined the effects of testosterone (T) and prolactin (PRL) on CPD expression, and the role(s) of CPD in NO production and survival of prostate cancer (PCa) cells.METHODS: LNCaP cells were treated with T and/or PRL. CPD expression was measured. Regulation by T (low doses) was determined using transfected cells overexpressing 5α‐reductase type‐1 (5αR1), which converts T to the more potent dihydrotestosterone. The effects of siRNAs targeting CPD (siCPDs) on NO production, cell viability, and apoptosis were determined using DAF2‐DA, MTS, and Annexin‐V assays. The effects of PRL/T on CPD/NO levels in PC‐3, MDA‐PCa‐2b, and 22Rv1 cells were also evaluated.RESULTS: In LNCaP cells, 10 nM T and 10 ng/ml PRL‐upregulated CPD mRNA/protein levels. In pTRE‐transfectants, 1 nM T‐upregulated CPD mRNA levels by ∼2‐fold over controls, whereas 0.1 nM T caused similar upregulation in pTRE‐5αR1‐transfectants. In LNCaP cells cultured in arginine‐free medium, addition of furylacryloyl‐Ala‐Arg (FAR; CPD substrate) increased NO levels. NO production, with FAR, was enhanced by PRL and/or T. siCPDs decreased NO production and cell viability, but increased apoptosis. QPCR analysis showed T/PRL‐upregulation of CPD in 22Rv1, MDA‐PCa‐2b, and PC‐3 cells. NO production was doubled by T/PRL in 22Rv1 cells, tripled by T in MDA‐PCa‐2b cells, and marginally increased by PRL in MDA‐PCa‐2b and PC‐3 cells.CONCLUSIONS: T and PRL upregulate CPD and NO levels in PCa cells. CPD increases NO production to promote PCa cell survival. Prostate 72:450–460, 2012.Keywords
This publication has 46 references indexed in Scilit:
- Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancerJournal of Clinical Investigation, 2009
- Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 TumorClinical Cancer Research, 2008
- Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I studyThe Lancet Oncology, 2007
- Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological GradeCancer Research, 2004
- Identification and Nuclear Localization of a Novel Prolactin and Cytokine-Responsive Carboxypeptidase DEndocrinology, 2001
- Prolactin Receptor Expression in the Developing Human Prostate and in Hyperplastic, Dysplastic, and Neoplastic LesionsThe American Journal of Pathology, 1999
- Prolactin and prolactin receptors are expressed and functioning in human prostate.Journal of Clinical Investigation, 1997
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- Androgen receptors in endocrine‐therapy‐resistant human prostate cancerInternational Journal of Cancer, 1991
- In situ photolabelling of the human androgen receptorJournal of Steroid Biochemistry, 1988